TTR and amyloidosis: As with all therapies for TTR amyloidosis, treatment response to tafamidis varies among patients, with approximately one-third of V30M ATTRv-PN treated with tafamidis showing complete cessation of disease progression, one-third exhibiting slowed progression, and one-third not responding [23].